Related Experiment Video
Updated: May 6, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Long-term anticoagulant therapy in patients with coronary artery disease
S E Husted1, B K Ziegler, A Kher
1Department of Medicine and Cardiology, University Hospital of Aarhus, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark. steen.husted@as.aaa.dk
Insights
Aspirin is standard for secondary prevention in coronary artery disease (CAD). Long-term anticoagulants like vitamin-K antagonists (VKAs) show potential but require careful consideration of bleeding risks versus benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Aspirin is a proven secondary prevention for coronary artery disease (CAD).
- Long-term anticoagulant therapy in CAD patients remains controversial due to trial heterogeneity.
- Evaluating risks and benefits of anticoagulants beyond aspirin is crucial.
Purpose of the Study:
- To review major studies on anticoagulant therapy for secondary prevention in CAD.
- To discuss the scientific basis for using vitamin-K antagonists (VKAs) or other anticoagulants.
- To analyze both the benefits and bleeding risks associated with these treatments.
Main Methods:
- Systematic review of large-scale clinical trials.
- Analysis of heterogeneous trial data concerning medications, patient populations, and endpoints.
- Evaluation of scientific literature on anticoagulant mechanisms and outcomes.
Main Results:
- Heterogeneity in trials complicates standardized recommendations for anticoagulants in CAD.
- Evidence suggests potential benefits of anticoagulants but highlights significant bleeding risks.
- Risk-benefit profiles vary depending on the specific anticoagulant and patient profile.
Conclusions:
- While aspirin is established, the role of long-term anticoagulants in CAD secondary prevention requires further clarification.
- Careful patient selection and risk-benefit assessment are essential for considering VKA or alternative anticoagulants.
- Future research should address trial design to provide clearer guidance on anticoagulant use in CAD.
Abstract:
Secondary prevention of coronary events in coronary artery disease (CAD) patients with aspirin is generally accepted because of ease of administration, predictable safety, and proven efficacy. The use of long-term anticoagulant therapy with heparins, vitamin-K antagonists (VKAs), or thrombin inhibitors is, however, more controversial. During the last 40 years, several trials have been conducted in order to evaluate the role of anticoagulant therapy in patients with CAD as a protection against subsequent death and thrombo-embolic complications. The conducted trials are heterogeneous in many ways, concerning comparative medications, patient populations, endpoints and follow-up, which makes a standardized recommendation on the basis of these studies difficult. This review is an overview of the largest and best studies on this topic and discusses the scientific background for a possible use of VKA or an alternative anticoagulant treatment in CAD patients, looking at both the beneficial effects and the risk of bleeding.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care